PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stute for form 1449A/PTO

NOV 2 8 2006

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known
Application Number	10/526,741
Filing Date	November 14, 2005
First Named Inventor	Hiroyuki ABURATANI, et al.
Art Unit	1642
Examiner Name	Peter J. Reddig
Attorney Docket Number	392.1002

			U.S. PATENT	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages Columns Lines Where Relevant
Initials *	Cite No.1	Number - Kind Code ² (If known)	MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-		•	
	Γ	US-			
		US-			
	1	US-			
	I	US-			
		US-			1
		US-			
		US-			

		FOREIGN P	ATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.'	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰
PR		W0 2004/0222597	03-18-2004	Chugai Seiyaku Kabushiki Kaisha	Abstract	Only
PR		. W0 00/23109	04-27-2000	The Regents of the Univ. of California		
						<u></u>
						

Examiner Signature	/Peter Reddig/	Date Considered	02/26/2007	
Olghataro	-	Considered	04/40/2001	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/526,741 INFORMATION DISCLOSURE Filing Date November 14, 2005 STATEMENT BY APPLICANT First Named Inventor Hiroyuki ABURATANI, et al. Art Unit 1642 (Use as many sheets as necessary) Examiner Name Peter J. Reddig Sheet Attorney Docket Number 392.1002

		,
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ:
	Lage et al.: "Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation" Virchows Archiv, vol. 438, no 6, June 2001, pages 568-573.	
	Filmus J: "Glypicans in growth control and cancer", Glycobiology, vol. 11, no. 3 March 2001,pages 19R-23R.	
	Blackhall F H et al.: "Heparan sulfate proteoglycans and cancer", British Journal of Cancer, vol. 85, no. 8, 19 October 2001, pages 1094-1098,	
	Xiang et al.: "Glypican-3 expression is silenced in human breast cancer", ONCOGENE, vol. 20, no. 50, 1 November 2001, pages 7408-7412.	
	Powell et al.: "Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor," Chest, vol. 121, no. 3 Suppl. March 2002, pages 6S-7S.	
	Lin H et al.: "Frequent silencing of the GPC3 gene in ovarian cancer cell lines", Cancer Research, vol. 59, no. 4, 15 February 1999, pages 807-810.	
	Zhu Z et al.: "Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer," Amercian Journal Of Surgery, vol. 184, no. 1, July 2002, pages 78-83.	
	,	
	·	-
		No.1 Inumber(s), publisher, city and/or country where published. Lage et al.: "Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of lumor differentiation" Virchows Archiv, vol. 438, no 6, June 2001, pages 568-573. Filmus J: "Glypicans in growth control and cancer", Glycobiology, vol. 11, no. 3 March 2001, pages 19R-23R. Blackhall F H et al.: "Heparan sulfate proteoglycans and cancer", British Journal of Cancer, vol. 85, no. 8, 19 October 2001, pages 1094-1098. Xiang et al.: "Glypican-3 expression is silenced in human breast cancer", ONCOGENE, vol. 20, no. 50, 1 November 2001, pages 7408-7412. Powell et al.: "Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor," Chest, vol. 121, no. 3 Suppl. March 2002, pages 6S-7S. Lin H et al.: "Frequent silencing of the GPC3 gene in ovarian cancer cell lines", Cancer Research, vol. 59, no. 4, 15 February 1999, pages 807-810. Zhu Z et al.: "Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal

Examiner Signature	/Peter Reddig/	Date Considered	02/26/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial ir reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JUN 1 9 2006

(Use as many sheets as necessary)

	 		,
4 .		_	
 1 1	1 01		

	Complete If Known
Application Number	10/526,741
Filing Date	March 4, 2005
First Named Inventor	Hiroyuki ABURATANI, et al.
Art Unit	1642
Examiner Name	Peter J. Reddig
Attorney Docket Number	392.1002

			U.S. PATENT	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages Columns Lines Where Relevant
Initials *	Cite No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US			
		US-	**		
		US-			,
	l	US-			
		US-		·	
		US-			
		US-	, .		
		US-			
		US-			
		US-			
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-		,	

		FOREIGN P	ATENT DOCUM	MENTS		
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
PR		WO 2004/022597 A1	03-18-2004	Chugal Selyaku Kabushiki		Abstr.
	<u> </u>					
					1	
					1	

/Peter Reddig/ Considered UZ/26/2007	Examiner Signature	/Peter Reddig/	Date Considered	02/26/2007
--	-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 18 if possible. *Applicant is to place a check mark here if English language

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DePARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PADE Complete If Known Application Number 10/526,741 INFORMATION DISCLOSURE Filing Date March 4, 2005 STATEMENT BY APPLICANT First Named Inventor Hiroyuki ABURATANI, et al. Art Unit 1642 (Use as many sheets as necessary) Examiner Name Peter J. Reddig of 2 392.1002 Sheet Attomey Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PR		LAGE, et al., "Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation", VIRCHOWS ARCHIV, vol. 438 no. 6 June 2001 (2001-06), pages 567-573.	
		·	
		·	
		i	
	-		
		·	
		·	

Examiner Signature	/Peter Reddig/	Date Considered	02/26/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{**}EXAMINEN: Initial ir reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.